Podcasts about promising

The National Security Hour with Blanquita Cullum – Things are heating up in Chile as China eyes control of a new Pacific hub, COPIAPORT-E. Promising eco-friendly infrastructure, green energy, and massive shipping capacity, it raises sharp questions. Will Argentina, Brazil, and neighbors embrace it? Can the U.S. afford to stay sidelined as Beijing expands influence in South America's trade and security landscape?

The National Security Hour with Blanquita Cullum – Things are heating up in Chile as China eyes control of a new Pacific hub, COPIAPORT-E. Promising eco-friendly infrastructure, green energy, and massive shipping capacity, it raises sharp questions. Will Argentina, Brazil, and neighbors embrace it? Can the U.S. afford to stay sidelined as Beijing expands influence in South America's trade and security landscape?

Hey my wonderful sweet babies, Follow Me:Instagram- fabvictoria94Twitter- VictoriaB_94Snapchat- fabvictoria94TikTok: FabVictoria94Facebook: Victoria BishopFacebook Page- Fabulous Victoria BroadcastsPatreon: Fabulous Victoria PodcastPodcast Name- Fabulous Victoria PodcastYouTube Main Channel: Fabulous VictoriaCashApp: $fabvictoria (optional)Music from Simply Kee Simone, Dessie Style, and Kaysie Amya on YouTube.Email me for business inquiries only:bishopvictoria94@gmail.comTHIS VIDEO IS NOT SPONSORED.

Bongani Bingwa speaks to Fatima Hassan, human rights lawyer and founder of the Health Justice Initiative, about the SA AIDS Conference currently underway with experts and delegates to confront South Africa’s HIV crisis head-on, examining both the progress made and the challenges that remain. While rising numbers reflect the ongoing spread of the virus, they also highlight the success of antiretroviral treatment in keeping millions alive who might otherwise have lost their lives. 702 Breakfast with Bongani Bingwa is broadcast on 702, a Johannesburg based talk radio station. Bongani makes sense of the news, interviews the key newsmakers of the day, and holds those in power to account on your behalf. The team bring you all you need to know to start your day Thank you for listening to a podcast from 702 Breakfast with Bongani Bingwa Listen live on Primedia+ weekdays from 06:00 and 09:00 (SA Time) to Breakfast with Bongani Bingwa broadcast on 702: https://buff.ly/gk3y0Kj For more from the show go to https://buff.ly/36edSLV or find all the catch-up podcasts here https://buff.ly/zEcM35T Subscribe to the 702 Daily and Weekly Newsletters https://buff.ly/v5mfetc Follow us on social media: 702 on Facebook: https://www.facebook.com/TalkRadio702 702 on TikTok: https://www.tiktok.com/@talkradio702 702 on Instagram: https://www.instagram.com/talkradio702/ 702 on X: https://x.com/Radio702 702 on YouTube: https://www.youtube.com/@radio702See omnystudio.com/listener for privacy information.

The 2025 Low-Carbon Real Estate Exhibition brought together more than 12,500 professionals at the Grand Palais to tackle a common challenge: designing sustainable and desirable living spaces. In this new episode of Com d'Archi, we look back at this rapidly growing event, which enlightens architects on concrete solutions for low-carbon construction.This 4th edition of SIBCA has established itself as a showcase for architectural and construction innovations that support the ecological transition. Wood, recycled aluminum, bio-based or reused materials, health and quality of life as design drivers: the avenues are diversifying and becoming more refined. Architects, developers, engineers, designers, and manufacturers presented their advances and compared their visions in a fruitful dialogue that went beyond the field of real estate alone.From Redman to Care Promotion, SOPREMA to Sybois or CoolRoof, Vitra to inventive start-ups such as Anga, Ostrea, and Le Pavé, the ecosystem revealed its dynamism. The importance given to heritage, with the Grand Palais as a backdrop, also served as a reminder that decarbonization applies at all levels, from historic monuments to new neighborhoods.Despite political turmoil, the sector is proving its ability to mobilize creativity and collective intelligence. For architects, this trade show offers a compendium of inspiring practices and potential partners, all of which are resources for designing resilient, low-carbon spaces that are rich in quality of use. It is an event that confirms that architecture is at the heart of building a desirable future.__This English version was generated using AI with voice cloning, preserving the speaker' timbre and the natural French accent. We are currently testing this technology. Please excuse any imperfections. We are working to improve this system so that we can expand our broadcasts to multiple languages. But our favorite Esther will be back soon in English!Speakers : Anne-Charlotte Depondt Audio production comdarchipodcastImage teaser © Anne-Charlotte Depondt ___If you like the podcast do not hesitate:. to subscribe so you don't miss the next episodes,. to leave us stars and a comment :-),. to follow us on Instagram @comdarchipodcast to find beautiful images, always chosen with care, so as to enrich your view on the subject.Nice week to all of you ! Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

Let us help you find YOUR home in Portugal...Whether you are looking to BUY, RENT or SCOUT, reach out to Carl Munson and connect with the biggest and best network of professionals that have come together through Good Morning Portugal! over the last five years that have seen Portugal's meteoric rise in popularity.Simply contact Carl by phone/WhatsApp on (00 351) 913 590 303, email carl@carlmunson.com or enter your detailsBecome a supporter of this podcast: https://www.spreaker.com/podcast/the-good-morning-portugal-podcast-with-carl-munson--2903992/support.Let us help you find YOUR home in Portugal...Whether you are looking to BUY, RENT or SCOUT, reach out to Carl Munson and connect with the biggest and best network of professionals that have come together through Good Morning Portugal! over the last five years that have seen Portugal's meteoric rise in popularity.Simply contact Carl by phone/WhatsApp on (00 351) 913 590 303, email carl@carlmunson.com or enter your details

Dr. Sumanta (Monty) Pal and Dr. Petros Grivas discuss innovative new intravesical therapies and other recent advances in the treatment of non-muscle invasive bladder cancer. TRANSCRIPT Dr. Sumanta (Monty) Pal: Hello and welcome. I'm Dr. Monty Pal here at the ASCO Daily News Podcast. I'm a medical oncologist and professor and vice chair of academic affairs at the City of Hope Comprehensive Cancer Center in Los Angeles. And I'm really delighted to be your new host here. Today's episode is going to really sort of focus on an area near and dear to my heart, something I actually see in the clinics, and that's bladder cancer. We're specifically going to be discussing non-muscle invasive bladder cancer, which actually comprises about 75% of new cases. Now, in recent years, there's been a huge shift towards personalized bladder-preserving strategies, including innovative therapies and new agents that really are reducing reliance on more primitive techniques like radical cystectomy and radiation therapy. And I'm really excited about this new trend. And really at the forefront of this is one of my dear friends and colleagues, Dr. Petros Grivas. He's a professor in the Department of Medicine and Division of Hematology Oncology at the University of Washington. It's going to take a while to get through all these titles. He's taken on a bunch of new roles. He is medical director of the International Program, medical director of the Local and Regional Outreach Program, and also professor in the Clinical Research Division at the Fred Hutch Cancer Center. Petros, welcome to the program. Dr. Petros Grivas: Thank you so much, Monty. It's exciting for me to be here. Dr. Sumanta (Monty) Pal: Just FYI for our audience, our disclosures are available in the transcript of this episode.  We're going to get right into it, Petros. Non-muscle invasive bladder cancer, this is a really, really challenging space. We see a lot of recurrence and progression of the disease over time, about 50% to 70% of patients do have some recurrence after initial treatment, and about 30% are ultimately going to progress on to muscle-invasive or metastatic disease. Now, I will say that when you and I were in training, non-muscle invasive bladder cancer was something that was almost relegated to the domain of the urologist, right? They would use treatments such as BCG (Bacillus Calmette-Guérin) in a serial fashion. It was rare, I think, for you and I to really enter into this clinical space, but that's all changing, isn't it? I mean, can you maybe tell us about some of the new therapies, two or three that you're really excited about in this space? Dr. Petros Grivas: Monty, you're correct. Traditionally and conventionally, our dear friends and colleagues in urology have been managing patients with non-muscle invasive bladder cancer. The previous term was superficial bladder cancer. Now, it has changed, to your point, to non-muscle invasive bladder cancer. And this has to do with the staging of this entity. These tumors in superficial layers of bladder cancer, not invading the muscularis propria, the muscle layer, which makes the bladder contract for urine to be expelled. As you said, these patients have been treated traditionally with intravesical BCG, one of the oldest forms of immunotherapy that was developed back in the 1970s, and this is a big milestone of immunotherapy development. However, over the years, in the last 50 years, there were not many options for patients in whom the cancers had progression or recurrence, came back after this intravesical BCG. Many of those patients were undergoing, and many of them still may be undergoing, what we call radical cystectomy, meaning removal of the bladder and the lymph nodes around the bladder. The development of newer agents over the last several years has given the patients the option of having other intravesical therapies, intravesical meaning the delivery of drugs, medications inside the bladder, aiming to preserve the bladder, keep the bladder in place. And there are many examples of those agents. Just to give you some examples, intravesical chemotherapy, chemotherapy drugs that you and me may be giving intravenously, some of them can be given inside the bladder, intravesical installation. One example of that is a combination of gemcitabine and docetaxel. These drugs are given in sequence one after the other inside the bladder, and they have seen significant efficacy, good results, again, helping patients keeping the bladder when they can for patients with what we call BCG unresponsive non-muscle invasive bladder cancer. And again, there's criteria that the International Bladder Cancer Group and the FDA developed, how to define when BCG fails, when we have BCG unresponsive non-muscle invasive bladder cancer. Dr. Sumanta (Monty) Pal: And we're actually going to get into some of the FDA requirements and development pathways and so forth. What I'm really interested in hearing, and I'm sure our audience is too, are maybe some of the new intravesical treatments that are coming around. I do think it's exciting that the gemcitabine and docetaxel go into the bladder indeed, but what are some of the top new therapies? Pick two or three that you're excited about that people should be looking out for in this intravesical space. Dr. Petros Grivas: For sure, for sure. In terms of the new up-and-coming therapies, there are a couple that come to mind. One of them is called TAR-200, T-A-R 200. This agent is actually a very interesting system. It's an intravesical delivery of a chemotherapy called gemcitabine, the one that I just mentioned a few minutes ago, that is actually being delivered through what we call a pretzel, which is like a rounded [pretzel-shaped] structure working like an osmotic pump, and that is being delivered inside the bladder intravesically by urologists. And this drug is releasing, through the osmotic release mechanism, this chemotherapeutic drug, gemcitabine, inside the bladder. And this can be replaced once every 3 weeks in the beginning. And the data so far from early-phase trials are really, really promising, showing that this agent may be potentially regulatory approved down the road. So TAR-200 is something to keep in mind. And similarly, in the same context, there is a different drug that also uses the same mechanism, and this osmotic release, this pretzel, it's just encoded with a different agent. The different agent is an FGFR inhibitor, a target therapy called erdafitinib, a drug that you and me may give in patients with metastatic urothelial carcinoma if they have an FGFR3 mutation or fusion. And that drug is called TAR-210. Dr. Sumanta (Monty) Pal: And can I ask you, in that setting, do you have to have an FGFR3 mutation to receive it? Or what is the context there? Dr. Petros Grivas: So for TAR-210, TAR-2-1-0, usually there is a checking to see if there is an FGFR3 mutation or fusion. And the big question, Monty, is do we have adequate tissue, right? From a limited tissue on what we call the TURBT, right, that urologists do. And now there is a lot of development in technology, for example, urine circulating tumor DNA to try to detect these mutations in the urine to see whether the patient may be eligible for this TAR-210. Both of those agents are not FDA approved, but there are significant promising clinical trials. Dr. Sumanta (Monty) Pal: So now let's go to a rapid-fire round. Give us two more agents that you're excited about in this intravesical space. What do you think? Dr. Petros Grivas: There is another one called cretostimogene. It's a long name. Dr. Sumanta (Monty) Pal: They really make these names very easy for us, don't they? Dr. Petros Grivas: They are not Greek names, Monty, I can tell you, you know. Even my Greek language is having trouble pronouncing them. The cretostimogene, it's actually almost what we call a growth factor, a GM-CSF. The actual name of this agent is CG0070. This is a replicating mechanism where GM-CSF is replicating in cells. And this agent has shown significant results again, like the TAR-200, in BCG unresponsive non-muscle invasive bladder cancer. I would say very quickly, two agents that actually were recently approved and they're already available in clinical practice, is nadofaragene firadenovec, another long name. That's a non-replicating vector that has the gene of interferon alfa-2b that stimulates the immune system in the bladder. It's given once every 3 months. And the last one that was, as I mentioned, already FDA approved, it's an interleukin-15 superagonist. It's another long name, which is hard to pronounce, but I will give it a try. It's a drug that was recently actually approved also in the UK. The previous name was N-803. It's given together with BCG as a combination for BCG unresponsive non-muscle invasive bladder cancer. Dr. Sumanta (Monty) Pal: This is a huge dilemma, I think, right? Because if you're a practicing, I'm going to say urologist for the moment, I guess the challenge is how do you decide between an IL-15 superagonist? How do you decide between a pretzel-eluting agent? How do you decide between that and maybe something that's ostensibly, I'm going to guess, cheaper, like gemcitabine and docetaxel? What's sort of the current thinking amongst urologists? Dr. Petros Grivas: Multiple factors play into our account when the decision is being made. I discuss with urologists all the time. It's not an easy decision because we do not have head-to-head comparisons between those agents. As you mentioned, intravesical chemotherapy with gemcitabine and docetaxel has been used over the years and this is the lowest cost, I would say, the cheapest option with good efficacy results. Obviously, the nadofaragene firadenovec every 3 months and the interleukin-15 superagonist, N-803, plus BCG have also been approved. The question is availability of those agents, are they available? Are they reimbursed? Cost of those agents can come into play. Frequency of administration, you know, once every 3 months versus more frequent. And of course, the individual efficacy and toxicity data, preference of the patients; sometimes the provider, the urologist, may have something that they may be more familiar with. But we lack this head-to-head comparison. Of course, I want to make sure I mention that radical cystectomy may still be the option for appropriate patients. So that complicates also the decision making and has to be individualized, customized, and personalized, taking into account all those factors. And there is not one size fitting all. Dr. Sumanta (Monty) Pal: So I think we discussed five intravesical therapies. As you point out, and you know, I'm going to get some calls about this: I think I referred to radical cystectomy as being a more primitive procedure. Not true at all. I think it's something that still is, you know, a mainstay of management in this disease space. But I guess it gets even more complicated, am I right, Petros? Because now we have systemic therapies that we can actually apply in this non-muscle invasive setting for at this point, refractory disease. Can you maybe just give us a quick two-minute primer on that? Dr. Petros Grivas: Absolutely, and systemic therapies now come into play, as you said. And a classical example of that, Monty, came from the KEYNOTE-057 trial that we published about 6 years ago. This is intravenous pembrolizumab, given intravascularly, intravenously, as opposed to the previously discussed intravesical administration of agents. Pembrolizumab was tested in that KEYNOTE-057 trial and showed efficacy about, I would say, one out of five patients, about 20%, had a complete response of the tumor in the bladder in a year after starting the treatment. Again, it's hard to compare across different agents, but obviously when we give something intravenously, there is a risk of toxicity, side effects systemically, what we call immune-related adverse events. And this can also play in the decision making, right? When you have intravesical agents versus intravascular agents, there is different toxicity profiles in terms of systemic toxicity. But intravenous pembrolizumab has been an option, FDA approved, since, if I remember, it was early 2020 when this became FDA approved. There are other agents being tested in this disease, but like atezolizumab through the SWOG study that Dr. Black and Dr. Singh led, but atezolizumab is not FDA approved for this indication. Again, this is for BCG unresponsive, high-risk, non-muscle invasive bladder cancer. Dr. Sumanta (Monty) Pal: So maybe teach us how it works, for instance, at an expert center like the Fred Hutch. When you see a patient with non-muscle invasive bladder cancer, there's obviously the option of surgery, there's the intravesical therapies, which I imagine the urology team is still really at the helm of. But then, I guess there has to be consideration of all options. So you've got to bring up systemic therapy with agents like pembrolizumab. In that context, are you involved that early on in the conversation? Dr. Petros Grivas: That's a great discussion, Monty. Paradigm is shifting as we mentioned together. The urologists have been treating these patients and still they are the mainstay of the treaters, the managers in this disease. But medical oncologists come to play more and more, especially with the FDA approval of intravenous pembrolizumab about 5 years ago [GC1]  [KM2] . We have the concept of multidisciplinary bladder cancer clinic here at Fred Hutch and University of Washington. This happens every Tuesday morning, and we're very excited because it's a one-stop shop for the patients. We have the urologist, a medical oncologist, radiation oncologist, and experts from radiology and pathology, and we all review cases specifically with muscle-invasive bladder cancer. But every now and then, we see patients with BCG unresponsive non-muscle invasive bladder cancer. And this is where we discuss and we talk to the patient about pros and cons of all those options. And that's a classic example where medical oncologists may start to see those patients and offer their input and expertise. In addition to that, sometimes we have clinical trials, we may see these patients because there are systemic agents that may be administered in this setting. We have the SunRISe trial program that includes also a systemically administered checkpoint inhibitor. So that's another example where we see patients either in the context of multi-clinic or in individual solo clinics to counsel the patients about the pros and cons of the systemically administered agents in the context of clinical trials. Usually checkpoint inhibitors are the class of agents that are being tested in this particular scenario. Dr. Sumanta (Monty) Pal: I can see a scenario where it's really going to require this sort of deep dive, much in the way that we do for prostate cancer, for instance, where the medical oncologist is involved very early on and planning out any sort of systemic therapy component of treatment or at the very least, at least spelling out those options. I think it's going to be really interesting to see what this space looks like 5 or 10 years down the road. In closing, I wanted to go through something that I think is so different in this space, at least for the time being, and that is the paradigm for FDA approval. When you and I have our fellows in the clinics, we always say, “Look, you know, the paradigm in this disease and that disease and the other disease needs to be phase 3 randomized trials, right? Big thousand patient experiences where you're testing clinical endpoints.” That's tough in non-muscle invasive bladder cancer, right? Because thankfully, outcomes can actually be quite good, you know, in this setting, right? It's tough to actually estimate overall survival in some of these early-stage populations. Tell me what the current regulatory bar is, and this is a tough thing to do in 2 minutes or less but tell me where you see it headed. Dr. Petros Grivas: You alluded to that before, Monty, when I was giving the background and we talked about the regulatory approval. And I have to very quickly go back in time about 10 years ago because it's important for context that can help us in other disease types too. We had workshops with the FDA and the NCI with the help of the International Bladder Cancer Group and other colleagues. And we try to define a framework, what endpoints are meaningful for those patients in this disease. It was a multidisciplinary, multiple stakeholders meeting, where we tried to define what is important for patients. What are the available agents? What are the trial designs we can accept? And what are the meaningful endpoints that the regulatory agencies can accept for regulatory approval? And that was critical in that mission because it allowed us to design clinical trials, for example, single-arm trials in a disease where there was no standard of care. There was intravesical valrubicin and chemotherapy anthracycline that was approved for many years, but was not practically used in clinical practice, despite being approved, the valrubicin. And because of that, the FDA allowed these single-arm trials to happen. And obviously the endpoint was also discussed in that meeting. For example, for carcinoma in situ, complete response, clinical complete response, because the bladder remains intact in many patients, clinical complete response was a meaningful primary endpoint, also duration of response is also very important. So what is the durable clinical complete response in 1 year or 18 months is relevant. And when you have papillary tumors like Ta or T1 with CIS, for papillary tumors, event-free survival becomes one of the key endpoints and you look at it over time, for example, at 12 or 18 months, what is the event-free survival? So clinical complete response, duration of response, event-free survival, depending on the CIS presence or papillary tumors, I think these are endpoints that have allowed us to design those trials, get those agents approved.  Now, the question going forward, Monty, and we can close with that is, since now we have the embarrassment of riches, many more options available compared to where we were 6 and 7 years ago, is now the time to do randomized trials? And if we do randomized trials, which can be the control group? Which of those agents should be allowed to be part of the control group? These are ongoing discussions right now with the NCI, with other agencies, cooperative groups, trying to design those trials and move forward from here.[GC3]  Dr. Sumanta (Monty) Pal: Well, it's awesome to have you here on the program so we can get some early looks into some of these conversations. I mean, clearly, you're at the table at a lot of these discussions, Petros. So I want to thank you for sharing your insights with us today. This was just tremendous. Dr. Petros Grivas: Thank you, Monty. You know, patients in the center, I just came back from the Bladder Cancer Advocacy Network meeting in Washington, D.C., and we discussed all those questions, the topics you very eloquently mentioned and asked me today, and patients gave us great feedback and patients guide us in that effort. Thank you so, so much for having me and congratulations for the amazing podcast you're doing. Dr. Sumanta (Monty) Pal: Oh, cheers, Petros, thanks so much.  And thank you to the listeners who joined us today. If you really like the insights that you heard on this ASCO Daily News Podcast, please rate, review, and subscribe wherever you get your podcasts. Thanks, everyone. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Find out more about today's speakers:      Dr. Sumanta (Monty) Pal  @montypal  Dr. Petros Grivas @PGrivasMDPhD   Follow ASCO on social media:     @ASCO on Twitter    ASCO on Bluesky   ASCO on Facebook     ASCO on LinkedIn     Disclosures:    Dr. Sumanta (Monty) Pal:   Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview  Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical  Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis  Dr. Petros Grivas: Consulting or Advisory Role: Merck, Bristol-Myers Squibb, AstraZeneca, EMD Serono, Pfizer, Janssen, Roche, Astellas Pharma, Gilead Sciences, Strata Oncology, Abbvie, Bicycle Therapeutics Replimune, Daiichi Sankyo, Foundation Medicine, Bicycle Therapeutics, Eli Lilly, Urogen Pharma, Tyra Biosciences Research Funding (Inst.): Bristol-Myers Squibb, Merck, EMD Serono, Gilead Sciences, Acrivon Therapeutics, ALX Oncology, ALX Oncology, Genentech Travel, Accommodations, Expenses: Gilead Sciences

Promising rate-cut expectations pushed Wall Street to fresh record highs, as weaker jobs data, including softer private payrolls, fueled hopes of the Federal Reserve easing and sent US bond yields lower. In company news, Broadcom delivered an upbeat forecast on strong AI demand. In commodities, oil prices eased as OPEC considered a potential output hike, while iron ore climbed to multi-week highs on hopes of improving Chinese demand. Back home, Australian shares are expected to open higher on Friday. The content in this podcast is prepared, approved and distributed in Australia by Commonwealth Securities Limited ABN 60 067 254 399 AFSL 238814. The information does not take into account your objectives, financial situation or needs. Consider the appropriateness of the information before acting and if necessary, seek appropriate professional advice.See omnystudio.com/listener for privacy information.

Raphaël Melançon, political analyst for Noovo and CTV Montreal. He is also the president and founder of Trafalgar Strategies.

While the Roadrunners weren't able to pull the upset against #19 Texas A&M, UTSA sure looked the part against an SEC foe. Winning in the trenches and mostly avoiding penalties, Jeff Traylor feels like his team has the right stuff to compete for a championship. UTSA will have a chance to prove their progression over the offseason this week as they welcome Texas State to the Alamodome for the home opener. Can UTSA avenge last year's awful loss in the I-35 Showdown? 04:20 A&M performance recap 34:08 Listener voicemails 46:03 Previewing the Texas State Bobcats 1:11:00 Score predictions Video: https://youtu.be/9MGWFtoFNK0 Learn more about your ad choices. Visit megaphone.fm/adchoices

While the Roadrunners weren't able to pull the upset against #19 Texas A&M, UTSA sure looked the part against an SEC foe. Winning in the trenches and mostly avoiding penalties, Jeff Traylor feels like his team has the right stuff to compete for a championship. UTSA will have a chance to prove their progression over the offseason this week as they welcome Texas State to the Alamodome for the home opener. Can UTSA avenge last year's awful loss in the I-35 Showdown? 04:20 A&M performance recap 34:08 Listener voicemails 46:03 Previewing the Texas State Bobcats 1:11:00 Score predictions Video: https://youtu.be/9MGWFtoFNK0

This week, LevelCap and Matimi0 discuss the latest round of Battlefield 6 leaks, China's big gamble on game development, the awesome update for Helldivers 2, and much more! Support us on Patreon for bonus content!  https://www.patreon.com/LevelWithMePodcast Join Our Discord and make suggestions for our next episode topics  https://discord.gg/nxBQZ6eh8H

In this episode, host Jonathan Sackier is joined by Andrew Dunbar, Assistant Professor in the Department of Hematopoietic Biology and Malignancy at the University of Texas MD Anderson Cancer Center, Houston, USA. Dunbar discusses his research into myeloproliferative neoplasms, what drives disease progression and resistance, and promising targets for treatment, while reflecting on the mission of his lab and what lies ahead for the field.  Timestamps  00:00 – Introduction  02:29 – One thing people should know about myeloproliferative neoplasms  05:01 – Dunbar's background and research focus  08:00 – What would Dunbar do if not science and medicine?  10:24 – The basics of myeloproliferative neoplasms  14:30 – Myeloproliferative neoplasm diagnosis and treatment  16:49 – What drives disease progression and resistance?  18:30 – The mission of Dunbar's lab  21:23 – Development of AJ1-11095  22:54 – Balancing the complexity of disease modelling with urgent clinical needs  24:03 – Promising targets and pathways  26:35 – What's on the horizon?  28:40 – Three wishes 

Chicago Bulls Eye Malik Beasley As Promising Addition, Enhancing Roster Potential by Jaggy Sports

Katrina is on a role in this short episode as she discusses the broken model of the "one-hour prophy". Listen as she discusses the dangers of blindly following this model and gives 5 ways to improve the appointments.  Resources: More Fast Facts: https://www.ataleoftwohygienists.com/fast-facts/ Katrina Sanders Website: https://www.katrinasanders.com  Katrina Sanders Instagram: https://www.instagram.com/thedentalwinegenist/ 

Katrina is on a role in this short episode as she discusses the broken model of the "one-hour prophy". Listen as she discusses the dangers of blindly following this model and gives 5 ways to improve the appointments.  Resources: More Fast Facts: https://www.ataleoftwohygienists.com/fast-facts/ Katrina Sanders Website: https://www.katrinasanders.com  Katrina Sanders Instagram: https://www.instagram.com/thedentalwinegenist/ 

The Florida citrus industry has seen some promising investments in this year's Legislative Session, and the Department of Health and Human Services reports the first human case of New World Screwworm in the U.S.

On today's podcast, Charlie discusses the Green Bay Packers getting Micah Parsons, the Wisconsin Badgers' start, and the Milwaukee Brewers' World Series preview with the Toronto Blue Jays Charlie starts the show discussing the Packers going all-in to get Micah Parsons. The impact that he brings to the defense. What it does for the Packers in the NFC. Why the Packers did it now plus what happens if it goes south. From there, Charlie touches on the Wisconsin Badgers' shutout victory over Miami (OH) and why he saw some promise. Lastly, he talks about what might be a World Series preview series with the Milwaukee Brewers and Toronto Blue Jays

The team discusses 2025 Impeccable Baseball and 2024-25 Panini Silhouette Basketball. 

You keep making plans. Telling yourself this week will be different. Promising your chair, your friends, and yourself that you're going to finish this draft. But somehow the days go by and nothing gets done. In this episode, Dr. Marvette Lacy breaks down the real reason behind the cycle of avoidance and broken promises. It's not laziness. It's not a lack of time. It's the deep hit your confidence has taken and the fear that your best might not be good enough. If you're tired of feeling like a disappointment and ready to finally trust yourself again, this episode will show you how to rebuild belief, reset your plan, and take your next step forward.   Dissertation Information Qual Scholars Community: https://qual-scholars.circle.so/ 10 Pages In 2 Days Writing Retreat: https://qualscholars.com/10pages/ The Finish Your Dissertation Institute: https://qualscholars.com/theinstitute/  Qual Scholars Website: https://qualscholars.com/  Qual Scholars' Instagram: https://instagram.com/qual_scholars/

The prime minister’s point man on trade met with his American counterpart in Washington; new details are released in a double murder in Barrie, Ont.,a woman dies of sepsis after giving birth. Plus, Taylor Swift and Travis Kelce get engaged.

In today's podcast, Dr. Lewis Blevins discusses relacorilant, a drug currently in development by Corcept Therapeutics for the treatment of hypercortisolism. Clinical trials to date have shown encouraging results, with improvements in blood pressure, glucose control, weight, and body composition. Corcept Therapeutics specializes in developing drugs that modulate the glucocorticoid receptor.   Stay tuned for the next Podcast on hypercortisolism, diabetes, hypertension and weight management.  

Coach Dodd reviews a successful scrimmage against Des Moines Lincoln where energy, effort, and several underclassmen stood out. He highlights the need to tighten discipline after some chippy moments and praises players who may step into varsity roles. Looking ahead to a heated Week 1 at Tumwa, Dodd outlines three keys to win: protect the ball, dominate head and yards and special teams, and eliminate unforced penalties. He invites fans to come out Friday night as the season kicks off.

Learn more about your ad choices. Visit megaphone.fm/adchoices

Alzheimer's disease is not a normal part of aging—and new research is showing how lifestyle, diet, and exercise may help prevent or delay cognitive decline. Want to learn more? Then please click on the podcast as two of Montana’s leading […] The post New Research is Promising in Battling Dementia/Alzheimer's first appeared on Voices of Montana.

In this episode of Onc Now, host Jonathan Sackier welcomes Komal Jhaveri, Breast Medical Oncologist and clinical investigator at Memorial Sloan Kettering Cancer Center, New York, USA. Known for her trailblazing work in HER2-positive, HER2-low, and hormone receptor-positive breast cancers, Komal Jhaveri discusses how molecular subtyping, antibody-drug conjugates, and precision trials are reshaping the field.     Timestamps  00:00 – Introduction  02:50 – What initially drew Komal into oncology   04:45 – The future of breast cancer care  06:13 – Possibility of personalised treatments for patients  07:40 – Antibody-drug conjugates  09:30 – How we define HER2 status  14:40 – HER2-low disease  17:40 – Targeted therapy combinations  20:54 – Endocrine resistance  23:18 – The realities of implementing new therapies   28:40 – Promising initiatives on the horizon  31:30 – Komal's key takeaways  

In this week's episode of Your Drone Questions. Answered, host Chris Breedlove sits down with Benton Szejk from Wingtra to talk about where the drone industry is headed.With all the uncertainty around regulations, supply chains, tariffs, and evolving executive orders, many drone pilots and professionals are wondering: what's next? Benton shares insights from the manufacturer's perspective on:-The impact of the Blue and Green lists for drone certification-Supply chain challenges and how Wingtra is preparing for the future-Recent executive orders and what they mean for UAS policy in the U.S.-Key features needed for BVLOS operations-Wingtra's latest technology, including obstacle avoidance, LTE connectivity, and AI-powered tools-How drones are being used for mapping, surveying, environmental monitoring, and even public safetyWhether you're a drone operator, educator, or just passionate about the future of UAS, this episode offers encouragement and practical insights into what's ahead for the industry.https://wingtra.comhttps://wingtra.com/ray/ https://info.duncan-parnell.com/acton/media/23538/WingtraRAY-Roadshow

By the time Maryanne was 16 years old, she had been arrested for murder. In and out of foster and adoptive homes since age 10, she had run away, been trafficked and assaulted, and finally pointed a gun at the latest man to take her into his car. She pulled the trigger and fled. But with no family to turn to and few dependable friends, it did not take long for the police to catch up with her.In court, the defense blamed neither traffickers, nor Maryanne, but Washington state itself—or rather, its foster care system, which parents thousands of children every year. The courts did not listen to that argument, but the award-winning journalist Claudia Rowe did.Washington state is not alone, of course. Each year, hundreds of thousands of children grow up in America's $30 billion foster care system, only to leave and enter its prisons, where a quarter of all inmates are former foster youth.Weaving Maryanne's story with those of five other foster kids across the country—including an 18-year-old sleeping on the New York City subways; a gangbanger-turned graduate student; and a foster child who is now a policy advisor to the White House—Rowe paints a visceral survival narrative showing exactly where, when, and how the system channels children into locked cells. Balanced with accounts from psychologists, advocates, judges, and foster parents, Wards of the State paves a road to reform by pulling back the curtain on our country's longstanding foster care-to-prison pipeline and the searing realities faced by kids who may be sitting in classrooms next to your own children.She is the author of "Wards of the State: The Long Shadow of American Foster Care." https://www.amazon.com/stores/author/B07F9XZYL4http://www.yourlotandparcel.org

This week's episode of America on the Road brings two all-new models to the forefront, both playing in dramatically different corners of the automotive spectrum — the 2025 Mazda CX-5 and the 2026 Hyundai Ioniq 9. Mildly refreshed for 2025, the CX-5 is a compact SUV that continues to punch above its weight with upscale styling, responsive driving dynamics, and an even more premium interior this year. Mazda hasn't radically altered the CX-5's formula, but the updates include a sleeker front fascia, more tech inside, and a Carbon Edition trim that hits the sweet spot between luxury and value. During his weeklong road test of the SUV, Host Jack Nerad spent a weekend putting the fun-to-drive CX-5 through its paces over the twisty roads of eastern San Diego County, where it proved once again why it's a perennial favorite among compact SUV shoppers and car journalists alike. On the other end of the spectrum is the 2026 Hyundai Ioniq 9, an all-electric three-row SUV that aims directly at the heart of the American family vehicle market. Built on Hyundai's E-GMP platform, the Ioniq 9 is large, loaded, and luxurious, with a spacious interior and cutting-edge technology. Guest co-host Matt DeLorenzo breaks down how this EV stacks up on the road, particularly in terms of range, ride comfort, and usability for larger families. Is this the long-awaited Tesla Model X alternative? Tune in to find out. This week's special guest is Frank Hanley, Senior Director at J.D. Power. He joins the show to talk about the latest findings from the J.D. Power Initial Quality Study, with a particular focus on how quality benchmarks are shifting in 2025. Hanley shares insights on which automakers are hitting the mark and which are falling behind as new tech becomes standard and customer expectations continue to rise. Driving News Ford's $5 Billion EV Gamble: Did the Revolution Fall Short? Promising a “Model T Moment,” Ford doubled down this week on battery-electric vehicles, announcing a$5 billion investment aimed at revitalizing its EV efforts after cooling enthusiasm and slower-than-expected sales. The new plan involves nearly 4,000 jobs and renewed focus on its Louisville Assembly Plant and BlueOval Battery Park in Michigan. GM Reboots Autonomous Ambitions After Cruise Meltdown
 In a surprising move, General Motors is reviving its self-driving initiative following the well-publicized issues with its Cruise autonomous vehicle operation closed down. The pivot includes a shift in leadership and a new business model that could either reset the playing field or repeat past mistakes. Mercury Insurance Names Most Affordable Cars to Insure for 2025
 Mercury Insurance has released its annual list of the most cost-effective vehicles to insure, revealing some surprises for value-conscious drivers. Chevrolet is among the brands that continue to rank highly thanks to its straightforward designs and strong parts availability. Dodge Muscles Up Durango for 2026 For 2026, Dodge is going full muscle by making a V8 standard across the entire Durango lineup, from the base GT to the 710-horsepower Hellcat. The new 5.7-liter HEMI in the GT delivers a big jump in power and towing, while the R/T now features the 475-horsepower 392 HEMI under $50K. At the top, the Hellcat returns with a Jailbreak customization package and retains its crown as the most powerful gas SUV ever built. Listener Question of the Week This week's listener question comes from Jinnie in Park City, Utah, who asks: ““I think my car needs some attention and I'm not sure what to do about it. Should I go to the dealership for service or find a local mechanic?” Jack and Matt share some practical advice, including the best times to go to a dealer and the best ways to find a good independent mechanic you can trust. Check Out Matt's Book: Pick up a copy of co-host Matt DeLorenzo's terrific new book How to Buy an Affordable Electric Car: A Tightwad's Guide to EV Ownership.

In this episode, host Jonathan Sackier is joined by Emanuele Angelucci, Director of Hematology and Cellular Therapies and Director of the Stem Cell Transplant and Cellular Therapies Program at the Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Ospedale Policlinico San Martino Hospital in Genoa, Italy.   Timestamps   00:00 – Introduction 02:14 – The future of stem cell transplantation 03:15 – What continues to drive Emanuele in his work 05:40 – Donation of haematopoietic stem cells 10:00 – Gene therapy for haemoglobinopathies 11:40 – Will stem cell transplantation remain central in treating thalassaemia and sickle cell disease? 14:14 – Emanuele's work on iron overload and toxicity 16:53 – Current landscape for haemoglobinopathies 22:11 – Key recommendations in the most recent clinical guidelines for haemoglobinopathies  25:00 – Promising developments on the horizon for patients with haemoglobinopathies  28:00 – Emanuele's key takeaways 

For only the 3rd time in 80ish years, a Milwaukee restaurant chain will eat its words, sort of. Promising free burgers for EVERYONE if the Brewers win 12 straight, it will now pay up. Also, did Shohei Ohtani pitch to Mike Trout? Yeah, that happened. To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

HOUR 3 of the Chris Hand Show 08-13-2025| aired on Wednesday on SuperTalk 99.7 WTNSee omnystudio.com/listener for privacy information.

The Old Farmer's Almanac is predicting a ton of snow this winter. AOL dialup internet is going away for good. Starbucks in South Korea are banning customers that appear to be "café squatters". NASA Intern stole lunar rocks for his girlfriend after promising her the moon.See omnystudio.com/listener for privacy information.

Join John Harris for a packed episode of Texans All-Access featuring expert analysis of the Vikings preseason game from Andre Ware, Andy Kalu, and John McClain. Get insider reactions to rookie tackle Ariontae Ursery's impressive debut, Davis Mills' sharp opening drive, and standout performances from running back Dare Ogunbowale and receivers Braxton Berrios and John Metchie III. The crew discusses tough upcoming roster decisions at key positions, the defensive line's strength, and the concerning injury to fan-favorite tight end Brevin Jordan during Monday's practice. Plus, hear Kalu's pronunciation guide for international pathway player Ndubuisi Okoli who recorded a sack in his NFL debut. Essential listening for Texans fans preparing for Thursday's joint practice against the Carolina Panthers.See omnystudio.com/listener for privacy information.

HR3 - Falcons' attack style defense looks promising after first preseason game In hour three Mike Johnson, Beau Morgan, and Ali Mac let listeners call in and talk about if they have a weighted vest, their experience with weighted vests, and if they like weighted vests. Mike, Beau, and Ali also let listeners call in and talk about which players they're rooting for throughout all the NFL training camps, which Falcons players they have their eyes on, and which Falcons players they're excited for or concerned about after the first preseason game in the Wake Up Call! Then, The Morning Shift crew continues this Monday edition of The Morning Shift by spending some time with former Atlanta Falcons quarterback, and now analyst for the Atlanta Falcons Radio Network Dave Archer! Ali, Mike, Beau, and Dave discuss the Morice Norris injury, how the Falcons first preseason game ended on Friday with the Morice Norris injury, what Dave's takeaways were from the Falcons first preseason game, who Dave's standout player was from the Falcons first preseason game, how Dave felt about Jalon Walker and James Pearce Jr.'s performance on Friday in the Falcons' first preseason game, how Dave felt about the performances of the Falcons' wide receivers on Friday night in the Falcons' first preseason game, and the depth of the Falcons' wide receiver room. The Morning Shift crew also continues to give you their biggest takeaways from the Atlanta Falcons' first preseason game against the Detroit Lions on Friday night, and talk about how the Falcons' upcoming joint practices with Tennessee Titans this week will mimic a preseason game for Atlanta's starters. Finally, Mike, Beau, and Ali close out hour three by diving into the life of Beau “Squidbilly” Morgan in The Life of Squid!

President Trump says he is cracking down on crime and homelessness in the nation's capitol. The AP's Jennifer King reports.

View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter Eric Verdin is a physician-scientist and the CEO of the Buck Institute for Research on Aging whose career has centered on understanding how epigenetics, metabolism, and the immune system influence the aging process. In this episode, Eric traces his scientific journey from studying viruses and histone deacetylases (HDACs) to leading aging research at the Buck Institute, offering insights into how aging impairs immune and nervous system function—including thymic shrinkage, chronic inflammation, and reduced vaccine response—and how these changes impact lifespan. He explores the metabolic underpinnings of aging, such as oxidative stress and insulin and IGF-1 signaling, and he discusses practical tools like zone 2 cardio, ketogenic diets, and GLP-1 drugs. The conversation also covers declining NAD levels with age, the roles of NAD-consuming enzymes such as sirtuins and CD38, and what current NAD-boosting strategies (like NMN, NR, and IV NAD) can and can't accomplish. Eric weighs in on promising longevity interventions including rapamycin, growth hormone for thymic regeneration, and anti-inflammatory therapies, while also examining the promise and limitations of current biological age tests and the potential of combining epigenetic, proteomic, and organ-specific metrics with wearables to guide personalized longevity care. We discuss: Eric's scientific journey from virology to the field of geroscience [2:45]; How dysfunction in the immune system and central nervous system can drive aging throughout the body [5:00]; The role of metabolism and oxidative stress in aging, and why antioxidant strategies have failed to deliver clear benefits [8:45]; Other aspects of metabolism linked to aging: mitochondrial efficiency, fuel utilization, and glucose-modulating drugs [16:30]; How inefficient glucose metabolism drives insulin, IGF-1 signaling, and accelerates aging [21:45]; The metabolic effects of GLP-1 agonists, and the need to move beyond crude metrics like BMI in favor of more precise assessments of metabolic health [27:00]; The case for immune health as a “fifth horseman” [36:00]; How the innate and adaptive immune systems work together to build immune memory [39:45]; Why vaccines lose effectiveness with age: shrinking of the thymus gland and diminished T-cell diversity [44:15]; Exploring growth hormone, thymic regeneration, and the role of exercise in slowing immune aging [48:45]; The challenges of identifying reliable biomarkers for immune function, and the potential of rapamycin analogs to enhance vaccine response in older adults [57:45]; How rapamycin's effects on the immune system vary dramatically by dosage and frequency [1:03:30]; The limitations of mouse models in aging research and the need for cautious interpretation of rapamycin's benefits in humans [1:08:15]; NAD, sirtuins, and aging: scientific promise amid commercial hype [1:15:45]; How CD38 drives age-related NAD decline, influences immune function, and may impact longevity [1:23:45]; How NMN and NR supplementation interact with CD38 and NAD metabolism, and potential risks like homocysteine elevation and one-carbon cycle depletion [1:31:00]; Intravenous NAD: limited evidence and serious risks [1:37:00]; Interleukin-11 (IL-11) as a new target in immune aging, the dual role of chronic inflammation in aging, and the need for better biomarkers to guide interventions [1:43:00]; Biological aging clocks: types of clocks, promise, major limitations, and future outlook [1:48:30]; The potential of proteomics-based aging clocks for detecting organ-specific decline and frailty [2:00:45]; and More. Connect With Peter on Twitter, Instagram, Facebook and YouTube

Cracked Racquets Editor-in-Chief Alex Gruskin recaps Friday's action from Montreal and Toronto. He offers his thoughts on the day's most impressive performances, previews a very promising Week 2 in Canada, plus SO much more!! Don't forget to give a 5 star review on your favorite podcast app! In addition, add your twitter/instagram handle to the review for a chance to win some FREE CR gear!! Episode Bookmarks: WTA Montreal - 6:03 ATP Toronto - 21:25 WTA ITF Events - 35:04 ATP Challenger Events - 37:06 _____ Laurel Springs Ranked among the best online private schools in the United States, Laurel Springs stands out when it comes to support, personalization, community, and college prep. They give their K-12 students the resources, guidance, and learning opportunities they need at each grade level to reach their full potential. Find Cracked Racquets Website: https://www.crackedracquets.com Instagram: https://instagram.com/crackedracquets Twitter: https://twitter.com/crackedracquets Facebook: https://Facebook.com/crackedracquets YouTube: https://www.youtube.com/c/crackedracquets

Tom Appel, Publisher of Consumer Guide Automotive and host of the Consumer Guide Car Stuff podcast, joins Jon Hansen to discuss the increase in autonomous semi-trucks and the role humans play in the situation. Tom explains the potential benefits of self-driving trucks and also comments on a crazy car repossession story.

Promising answers, healing, and fulfillment, witchcraft and new age practices captivate our culture. And many spiritually hungry people--even in the church--unknowingly participate in these dark and dangerous spiritual activities, with dark and dangerous consequences.Recounting her own escape from the occult, former new age witch, our guest, Tailah Scroggins will expose the lies and secrets of the modern-day occult, revealing the ancient demonic origins and influences behind astrology, tarot cards, psychics, crystals, yoga, and more. With compassion and insight, she will remind us that when you let the light of Jesus shine in you and through you, the darkness won't be able to overcome it--and you'll find the true healing, answers, and spiritual fulfillment you long for.Become a Parshall Partner: http://moodyradio.org/donateto/inthemarket/partnersSee omnystudio.com/listener for privacy information.

This week on Brian's World we update you on the latest out of Chiefs training camp as Josh Simmons appears to be the Chiefs locked in starter at left tackle. Omarr Norman-Lott is also turning some heads at practice and the complicated legacy of Hulk Hogan. Learn more about your ad choices. Visit megaphone.fm/adchoices

ESPN journalists Albert Fabrega and Juan Fossaroli join Tom Clarkson in the Spa paddock to dissect another huge weekend in the title fight between McLaren teammates Oscar Piastri and Lando Norris at the Belgian Grand Prix. Piastri went into the weekend eight points clear of Lando at the top of the Drivers' Standings, but after beating him in both the Sprint and Grand Prix, that advantage has now doubled to 16 points. How did Oscar ‘lure' him into that crucial overtake on the first lap of racing? Did ‘little errors' prove too costly for Lando? Or should McLaren have double stacked their pit stop to give him a better chance of fighting for the win? Charles Leclerc secured his fifth podium of the season with P3. How much was Ferrari's performance down to their eagerly anticipated new rear suspension? What do the guys make of a rollercoaster weekend for Lewis Hamilton?  And with Max Verstappen winning the Sprint and finishing P4, what will new Red Bull Team Principal Laurent Mekies take away from his first Grand Prix in charge of the team? Will Max be encouraged by his own performance as Red Bull's new era gets underway? Listen to more official F1 podcasts In-depth interviews with F1's biggest stars on F1 Beyond The Grid Your F1 questions answered by the experts on F1 Explains F1 THE MOVIE, STARRING BRAD PITT - OUT NOW Don't miss the chance to see F1 on the big screen. Get tickets now It's All To Drive For in 2025. Be there! Book your seat for a Grand Prix this season at tickets.formula1.com

Murphy and Jodi battle about exercise equipment in their home. #family fitnessSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter Brian Kennedy is a renowned biologist, leader in aging research, and director of the Center for Healthy Longevity at the National University of Singapore. In this episode, Brian shares insights from ongoing human aging studies, including clinical trials of rapamycin and how dosing strategies, timing, and exercise may influence outcomes. He presents two key models of aging—one as a linear accumulation of biological decline and the other as an exponential rise in mortality risk—and explains why traditional models of aging fall short. He also explains why most current aging biomarkers lack clinical utility and describes how his team is working to develop a more actionable biological clock. Additional topics include the potential of compounds like alpha-ketoglutarate, urolithin A, and NAD boosters, along with how lifestyle interventions—such as VO2 max training, strength building, and the use of GLP-1 and SGLT2 drugs—may contribute to longer, healthier lives. We discuss: Brian's journey from the Buck Institute to Singapore, and the global evolution of aging research [2:45]; Rethinking the biology of aging: why models like the hallmarks of aging fall short [9:45]; How inflammation and mTOR signaling may play a central, causal role in aging [14:15]; The biological role of mTOR in aging, and the potential of rapamycin to slow aging and enhance immune resilience [17:30]; Aging as a linear decline in resilience overlaid with non-linear health fluctuations [22:30]; Speculating on the future of longevity: slowing biological aging through noise reduction and reprogramming [33:30]; Evaluating the role of the epigenome in aging, and the limits of methylation clocks [39:00]; Balancing the quest for immortality with the urgent need to improve late-life healthspan [43:00]; Comparing the big 4 chronic diseases: which are the most inevitable and modifiable? [47:15]; Exploring potential benefits of rapamycin: how Brian is testing this and other interventions in humans [51:45]; Testing alpha-ketoglutarate (AKG) for healthspan benefits in aging [1:01:45]; Exploring urolithin A's potential to enhance mitochondrial health, reduce frailty, and slow aging [1:05:30]; The potential of sublingual NAD for longevity, and the combination of NAD and AKG for metabolic and exercise enhancement [1:09:00]; Other interventions that may promote longevity: spermidine, 17

Promising “restrictions?”      To advertise on our podcast, please reach out to sales@advertisecast.com or visit https://www.advertisecast.com/TheJeffWardShow

The news to know for Tuesday, July 1, 2025! We're talking about a marathon in Congress as President Trump's big budget bill faces some new hurdles.  Also, the end of an era for an agency meant to improve lives around the world—what past presidents are saying about it, and what the Trump administration plans next.  Plus—a big campaign finance case is headed for the Supreme Court, a new kind of flu vaccine is showing promise, and the WNBA is getting bigger than ever.    Those stories and even more news to know in about 10 minutes!    Join us every Mon-Fri for more daily news roundups!  See sources: https://www.theNewsWorthy.com/shownotes Become an INSIDER to get AD-FREE episodes here: https://www.theNewsWorthy.com/insider Get The NewsWorthy MERCH here: https://thenewsworthy.dashery.com/ Sponsors: Go to HiyaHealth.com/NEWSWORTHY to get 50% off your first order of their best-selling children's vitamin. Trade is exclusively offering our listeners 50% off your one month trial at drinktrade.com/newsworthy To advertise on our podcast, please reach out to ad-sales@libsyn.com